	US 12,246,022 B2
	Compositions and methods for treating, preventing or reversing age associated inflammation and disorders
John M. Sedivy, Barrington, RI (US); and Marco De Cecco, Pawtucket, RI (US)
Assigned to BROWN UNIVERSITY, Providence, RI (US)
Filed by BROWN UNIVERSITY, Providence, RI (US)
Filed on Sep. 19, 2023, as Appl. No. 18/470,182.
Application 18/470,182 is a continuation of application No. 16/934,826, filed on Jul. 21, 2020, granted, now 11,793,814.
Application 16/934,826 is a continuation in part of application No. PCT/US2020/015043, filed on Jan. 24, 2020.
Claims priority of provisional application 62/907,251, filed on Sep. 27, 2019.
Claims priority of provisional application 62/797,109, filed on Jan. 25, 2019.
Prior Publication US 2024/0197745 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/52 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/52 (2013.01) [A61K 31/513 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)]

20 Claims

1. A method for slowing down the progression of and/or lessening the symptoms of Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorder, dementia with Lewy Bodies, frontotemporal dementia, mild cognitive impairment, Parkinson's disease, progressive supra nuclear palsy, Rett Syndrome, or Aicardi-Goutieres syndrome in a patient in need thereof, the method comprising administering a therapeutically effective amount of censavudine to the patient.